Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion submitted an application for a Phase 3 Clinical Trial Plan (Part 1) to the European Medicines Agency (EMA) for CT-P44, a biosimilar candidate referencing Darzalex, targeting patients with refractory or relapsed multiple myeloma. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up…

Read More “[Disclosure] Celltrion (068270) – Submission of Application for Phase 3 Clinical Trial Plan for CT-P44 (Darzalex Biosimilar) in Europe (Part 1) / 2024-11-28” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion issued a correction disclosure regarding its Investor Relations (IR) presentation held on November 27, 2024, to update the event proceeding details (Korean-English interpretation provided for both presentation and Q&A session). 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…

Read More “[Disclosure] Celltrion (068270) – (Correction) Investor Relations (IR) Presentation / 2024-11-27” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary At Investor Day in Hong Kong, Celltrion announced mid-to-long-term revenue targets of KRW 3.5T for 2024, KRW 5T for 2025, and KRW 7T for 2026, alongside plans to launch a CDMO business with an initial KRW 1.5T investment via a wholly-owned subsidiary and consider retiring approximately…

Read More “[Disclosure] Celltrion (068270) – Forward-Looking Business and Management Plan (Fair Disclosure) / 2024-11-27” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion will host its Hong Kong Investor Relations (IR) presentation via live stream on its official YouTube channel on November 27, 2024, at 16:00 (KST). 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring IR Presentation Materials and Business Updates…

Read More “[Disclosure] Celltrion (068270) – Investor Relations (IR) Presentation / 2024-11-26” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Regarding media reports on a KRW 200B Redeemable Convertible Preferred Shares (RCPS) issuance, Alteogen clarified that while the issuance is under consideration, nothing has been concretely finalized and no lead manager contract has been executed with Shinhan Securities. 📊 [Key Disclosure Details & Financial Highlights] 📝…

Read More “[Disclosure] ALTEOGEN (196170) – Clarification on Rumors or News Reports (Unconfirmed) / 2024-11-21” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion decided to acquire approximately KRW 100 billion (583,431 common shares) worth of its own shares on the open market to stabilize its stock price and enhance shareholder value. The acquisition period runs from November 22, 2024, to February 21, 2025. 📊 Key Disclosure Content &…

Read More “[Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2024-11-21” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received marketing authorization from the Ministry of Food and Drug Safety (MFDS) for Stoboclo and Osenvelt (CT-P41), biosimilars referencing Prolia and Xgeva. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Marketing Authorization Official Reflection and Subsequent Disclosures…

Read More “[Disclosure] Celltrion (068270) – Domestic (MFDS) Marketing Authorization for Stoboclo & Osenvelt (CT-P41, Prolia & Xgeva Biosimilar) / 2024-11-21” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed the signing of a pharmaceutical contract manufacturing agreement with a Europe-based pharmaceutical company valued at approx. KRW 752.4B (USD 540,540,000), representing 20.37% of its FY2023 consolidated revenue. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring…

Read More “[Disclosure] Samsung Biologics (207940) – Single Sales and Supply Contract / 2024-11-20” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed the signing of a pharmaceutical contract manufacturing agreement with a Europe-based pharmaceutical company valued at approx. KRW 178B (USD 127,850,000), representing 4.82% of its FY2023 consolidated revenue. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring…

Read More “[Disclosure] Samsung Biologics (207940) – Single Sales and Supply Contract / 2024-11-20” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen set December 3, 2024, as the record date to determine eligible shareholders entitled to vote at the upcoming Extraordinary General Meeting of Shareholders. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Eligible Shareholder Determination and Convocation Notice…

Read More “[Disclosure] ALTEOGEN (196170) – Setting of Record Date for Shareholders / 2024-11-18” »